Company Profile

B3 Bio Inc
Profile last edited on: 10/5/16      CAGE: 55RB8      UEI:

Business Identifier: RNA oligonucleotide based drugs
Year Founded
2007
First Award
2010
Latest Award
2010
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6 Davis Drive
Research Triangle Park, NC 27709
   (919) 226-3079
   N/A
   www.b3bio.com
Location: Single
Congr. District: 04
County: Durham

Public Profile

b3bio is a privately-held biotechnology company with an expertise in the field of RNA therapeutics. The company’s technology platform, which is licensed from Duke University and the University of Texas, is aimed at developing an entirely new class of medicines which employ small RNA molecules to target individual cells and tissues with remarkable precisio

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $183,938
Project Title: Modular Internalizing Molecules For Treatment Of More Than One Stage Of Malignanc

Key People / Management

  Dani P Bolognesi -- CEO & Chairman

  Robert Bonczek -- Chief Financial Officer Co-Founder

  Michael L Greenberg -- Head of Research & Development

Company News

There are no news available.